{"prompt": "['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '107', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', '9', 'STATISTICAL ANALYSIS PLAN', 'NOTE: Data from an interim safety and futility eDMC for LEAP-007 (data cutoff: 19-', 'MAY-2021) indicated that the study met the prespecified nonbinding futility criteria for', 'os for the combination of lenvatinib plus pembrolizumab compared with placebo plus', 'pembrolizumab. This futility analysis was requested at a previous eDMC meeting and', 'conducted as described in the sSAP. Based upon these data and the recommendation of', 'the eDMC, Amendment 007-06 was implemented to unblind the study and remove', 'lenvatinib and matching placebo from the treatment arms. The prespecified interim', 'and final analyses of the study described in the statistical analysis plan (SAP) will not be', 'performed. Selected analyses of safety and ePRO endpoints will be performed at the', 'end of the study; there will be no further analyses of efficacy endpoints.', 'This section outlines the statistical analysis strategy and procedures for the study. As of', 'Amendment 007-06, the study has been unblinded. Changes made to primary and/or key', 'secondary hypotheses, or the statistical methods related to those hypotheses, that occurred', 'prior to study unblinding were documented in previous protocol amendment(s) (consistent', 'with International Council for Harmonisation [ICH] of Technical Requirements for', 'Pharmaceuticals for Human Use Guideline E9). Changes to exploratory or other', 'nonconfirmatory analyses made after the protocol has been finalized, but before', 'unblinding/final database lock, will be documented in a supplemental statistical analysis plan', '(sSAP) and referenced in the clinical study report (CSR) for the study. Post hoc exploratory', 'analyses will be clearly identified in the CSR. Separate analysis plans (ie, separate', 'documents from the sSAP) will be developed to detail PK and biomarker analyses. The', 'ePRO analysis plan will be included in the sSAP.', '9.1', 'Statistical Analysis Plan Summary', 'Key elements of the SAP are summarized below. The comprehensive plan is provided in', 'Sections 9.2 through 9.12. As of Amendment 007-06, the prespecified interim and final', 'analyses of the study described in SAP will not be performed. Selected analyses of', 'safety and ePRO endpoints will be performed at the end of the study; there will be no', 'further analyses of efficacy endpoints. The SAP summary has been updated', 'accordingly.', 'Study Design Overview', 'Phase 3 study of pembrolizumab plus lenvatinib VS pembrolizumab plus placebo', 'for 1L treatment of metastatic NSCLC in participants whose tumors express', 'PD-L1 (TPS 21%)', 'Treatment Assignment', 'Approximately 620 participants will be randomized in a 1:1 ratio between', '2 treatment arms: (1) pembrolizumab + lenvatinib and (2) pembrolizumab +', 'placebo.', 'Stratification factors are as follows:', 'Geographic region (East Asia VS non-East Asia)', 'ECOG PS (0 VS 1)', 'TPS (1%-49% vs >50%)', 'As of Amendment 007-06, the study is unblinded and all ongoing participants', 'will continue treatment with open-label pembrolizumab monotherapy.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '108', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'Analysis Populations', 'Efficacy: Intention-to-Treat (ITT)', 'Safety: All Participants as Treated (APaT)', 'Primary Endpoints', 'PFS per RECIST 1.1 based on BICR', 'os', 'Secondary Endpoints', 'OR per RECIST 1.1 based on BICR', 'Safety and tolerability', 'Change from baseline in Global health status/QoL, cough, chest pain, dyspnea', 'and physical functioning scores', 'Time to True Deterioration (TTD) in global health status/QoL, cough, chest', 'pain, dyspnea, and physical functioning', 'TTD in the composite endpoint of cough, chest pain, or dyspnea items', 'Statistical Methods for', 'As of Amendment 007-06, the prespecified interim and final analyses of the', 'Key Efficacy Analyses', 'study will not be performed. There will be no further analyses of efficacy', 'endpoints.', 'The primary hypotheses will be evaluated by comparing pembrolizumab +', 'lenvatinib to pembrolizumab + placebo in PFS and os using a stratified log-rank', 'test and in ORR using the stratified Miettinen and Nurminen method [Miettinen,', 'O. 1985]. The HR will be estimated using a stratified Cox regression model. Event', 'rates over time will be estimated within each treatment group using the Kaplan-', 'Meier method. The difference in ORR will be estimated using the stratified', 'Miettinen and Nurminen method with strata weighting by sample size.', 'Statistical Methods for', 'The analysis of safety results will follow a tiered approach. The tiers differ with', 'Key Safety Analyses', 'respect to the analyses that will be performed. There are no events of interest that', 'warrant elevation to Tier 1 events in this study. Tier 2 parameters will be assessed', 'via point estimates with 95% CIs provided for between-group comparisons; only', 'point estimates by treatment group are provided for Tier 3 safety parameters. The', '95% CIs for the between-treatment differences in percentages will be provided', 'using the Miettinen and Nurminen method.', 'Interim Analyses', 'As of Amendment 007-06, no interim analyses of the study will be performed.', 'Multiplicity', 'As of Amendment 007-06, no interim or final analyses of the study will be', 'performed.', 'Sample Size and Power', 'As of Amendment 007-06, no interim or final analyses of the study will be', 'performed.', 'The planned sample size is approximately 620 participants. For PFS, based on 416', 'events, the study has 86.5% power to detect a HR of 0.7 (pembrolizumab +', 'lenvatinib VS pembrolizumab + placebo) at a=0.55% (1-sided). For OS, based on', '388 events, the study has 90% power to detect a HR of 0.71 (pembrolizumab +', 'lenvatinib VS pembrolizumab + placebo) at =1.95% (1-sided).', 'China Extension Study', 'As of Amendment 007-06, enrollment in the Extension Study in China has', 'been stopped.', 'China participants randomized during the global study phase will be included in', 'all global study analyses (efficacy and safety). China participants randomized', 'during the China extension phase will be excluded from all global study analyses.', 'China participants randomized during global and extension phases will both be', 'included in any China-specific analyses.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']\n\n###\n\n", "completion": "END"}